Optical transillumination and reflectance spectroscopy to quantify disease risk
CA 2467407 C · Owner: Wilson, Brian C. · Inventors: Wilson, Brian C.; Nielsen, Michelle K.; Lilge, Lothar
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention uses spectroscopic tissue volume measurements using nonionizing radiation to detect pre-disease transformations in the tissue which , increase the risk for this disease in mammals. The method illuminating a volume of selected tissue of a mammal with light having wavelengths covering a pre-selected spectral range, detecting light transmitted through or reflected , from, volume of selected tissue and obtaining a spectrum of the detected light. The spectrum of detected light is then represented by one or more basis spectral components, an error term, and an associated scalar coefficient for each of the basis spectral components. The associated scalar coefficient is …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 20, 2002 and granted September 25, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.